ArticleOncology letters2026
Superior cancer detection with transperineal biopsy in patients with an elevated prostate-specific antigen level and a PI-RADS score of 3-4: A retrospective cohort study.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The early and accurate detection of prostate cancer remains pivotal for improving clinical outcomes. The present study aimed to compare the cancer detection rates (CDRs) and safety profiles of transperineal (TP) vs. transrectal (TR) prostate biopsy techniques in patients with elevated prostate-specific antigen (PSA) levels and magnetic resonance imaging findings suggestive of malignancy (Prostate Imaging Reporting and Data System score 3 or 4). A retrospective cohort study was conducted on 127 patients who underwent TP (n=65) or TR (n=62) prostate biopsies between May 2022 and August 2024. CDR, adverse events and laboratory findings were compared between the groups. The TP approach yielded a significantly higher CDR (55.38%) than the TR approach (27.42%) (P=0.001), with no increase in adverse events, such as fever, infection or rectal bleeding. Routine lab values, including those for PSA and free PSA, showed no significant differences. In conclusion, in the present retrospective single-center cohort, the TP protocol used was associated with a higher cancer detection rate than the TR protocol, without an increased rate of adverse events. Given the non-randomized design and protocol differences between groups, these findings should be interpreted with caution and warrant confirmation in prospective multicenter studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.